Literature DB >> 2642731

Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma.

D L Ahmann1, E T Creagan, R G Hahn, J H Edmonson, H F Bisel, D J Schaid.   

Abstract

Five hundred three patients with advanced malignant melanoma were exposed to a number of clinical investigative chemotherapeutic regimens between 1971 and 1984 in an effort to assess the clinical activity of these regimens in this disease. Of the 503 patients participating in the studies, ten patients experienced a complete response. However, only three of these patients survived more than 5 years. Of this group of 503 patients, seven additional patients who did not experience a complete response survived more than five years. Of the ten patients surviving more than 5 years, two had immediate progression after institution of investigative regimens, whereas five remained stable for brief periods of time before progressive metastatic disease. Three patients experienced a complete response. It appeared that systemic therapeutic interventions in these trials were conspicuously ineffective for this large group of patients. A few long-term survivors attest to the capricious nature of this neoplasm and its association with likely spontaneous regressions. Although these long-term survivors did survive after institution of systemic chemotherapy, it is likely that this survival was related temporally, but perhaps not causally, to the institution of treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2642731     DOI: 10.1002/1097-0142(19890115)63:2<224::aid-cncr2820630203>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.

Authors:  Christina Kim; Christopher W Lee; Laurel Kovacic; Amil Shah; Richard Klasa; Kerry J Savage
Journal:  Oncologist       Date:  2010-06-10

Review 2.  Paraneoplastic granulocytosis in metastatic melanoma.

Authors:  Jeremy L Davis; R Taylor Ripley; Timothy L Frankel; Irina Maric; Jay N Lozier; Steven A Rosenberg
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

3.  [Long-term locally-recurrent melanoma].

Authors:  A G Bach; W C Marsch; C Richter; D Lübbe; P Helmbold
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

4.  Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.

Authors:  R Taylor Ripley; Jeremy L Davis; Jacob A Klapper; Aarti Mathur; Udai Kammula; Richard E Royal; James C Yang; Richard M Sherry; Marybeth S Hughes; Steven K Libutti; Donald E White; Seth M Steinberg; Mark E Dudley; Steven A Rosenberg; Itzhak Avital
Journal:  Ann Surg Oncol       Date:  2009-09-24       Impact factor: 5.344

5.  Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.

Authors:  Laura Harstad; Kenneth R Hess; Morris D Groves
Journal:  Neuro Oncol       Date:  2008-08-14       Impact factor: 12.300

Review 6.  Is observation really appropriate for small choroidal melanomas.

Authors:  J J Augsburger
Journal:  Trans Am Ophthalmol Soc       Date:  1993

7.  Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.

Authors:  G Fierlbeck; T Schreiner; G Rassner
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

8.  Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Authors:  D L Morton; L J Foshag; D S Hoon; J A Nizze; E Famatiga; L A Wanek; C Chang; D G Davtyan; R K Gupta; R Elashoff
Journal:  Ann Surg       Date:  1992-10       Impact factor: 12.969

9.  Membrane transport proteins associated with drug resistance expressed in human melanoma.

Authors:  D Schadendorf; A Makki; C Stahr; A van Dyck; R Wanner; G L Scheffer; M J Flens; R Scheper; B M Henz
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 10.  Metastatic melanoma.

Authors:  W Sun; L M Schuchter
Journal:  Curr Treat Options Oncol       Date:  2001-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.